摘要
肾癌是泌尿系统常见恶性肿瘤,干扰素免疫治疗是治疗晚期肾癌的主要方案之一,但是总体应答率不高。Janus蛋白酪氨酸激酶/信号转导和转录激活因子(JAK-STAT)信号途径是干扰素发挥其生物学作用的经典途径,肾癌的干扰素抵抗主要与JAK-STAT途径表达异常相关。另外,VHL(Von Hippel-Lindau)基因突变和干扰素相关调节基因的表达异常可能在干扰素抵抗中发挥了一定的作用。寻找能预测干扰素疗效的分子标志物成为研究热点,STAT3的多态性有望成为潜在的预测指标。
Renal cell carcinoma is a common malignant tumor in urinary system. The immunotherapy with interferon is the major treatment for advanced renal cell carcinoma. However,the overall response rate is poor. JAK-STAT signaling pathway is a classic pathway for biological activities induced by interferon. The interferon resistance of renal cell carcinoma is mainly associated with abnormal expression of JAK-STAT pathway. In addition,VHL mutation and interferon related regulative genes abnormal expression also play a critical role in interferon resistance. The studies on predictors for interferon resistance become popular in recent years,and STAT3 polymorphism is expected to be a potential predictor.
出处
《医学综述》
2014年第22期4077-4078,共2页
Medical Recapitulate
基金
广西自然科学基金(2010GXNSFB013080)
